The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the m
The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B) or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
대표청구항▼
1. A method for treating cancer in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of a compound of the Formula (II): or a pharmaceutically acceptable salt thereof, wherein the cancer is lung cancer, ovarian cancer, thyroid cancer, o
1. A method for treating cancer in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of a compound of the Formula (II): or a pharmaceutically acceptable salt thereof, wherein the cancer is lung cancer, ovarian cancer, thyroid cancer, or melanoma. 2. The method of claim 1, wherein the cancer comprises a genetic mutation. 3. The method of claim 2, wherein the genetic mutation comprises a RAS mutation, an EGFR mutation, a KRAS mutation, a p53 mutation, a BRAF mutation, a EVI1 mutation, a Flt-3 mutation, WT-1 mutation, a cyclin D mutation, a PTEN mutation, an ABL kinase mutation, or a chromosomal abnormality. 4. The method of claim 1, wherein the cancer is a multi-drug resistant (MDR) cancer. 5. The method of claim 1, wherein the cancer is relapsed and/or refractory cancer. 6. The method according to claim 1 further comprising administering at least one other therapy or therapeutic agent. 7. The method according to claim 6 further comprising administering radiation. 8. A method for treating cancer in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of a compound of the Formula (II): or a pharmaceutically acceptable salt thereof, wherein the compound is administered by systemic intravenous injection in a bolus or continuous infusion regimen, andwherein the cancer is acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, or biphenotypic acute leukemia. 9. The method of claim 8, wherein the cancer is acute myeloid leukemia. 10. The method of claim 9, wherein the acute myeloid leukemia is acute megakaryoblastic leukemia or promyelocytic leukemia. 11. The method of claim 8, wherein the cancer is biphenotypic acute leukemia. 12. The method of claim 8, wherein the cancer is chronic lymphocytic leukemia. 13. The method of claim 8, wherein the cancer is acute lymphoblastic leukemia. 14. The method of claim 8, wherein the cancer comprises a genetic mutation. 15. The method of claim 14, wherein the genetic mutation comprises a RAS mutation, an EGFR mutation, a KRAS mutation, a p53 mutation, a BRAF mutation, a EVI1 mutation, a Flt-3 mutation, WT-1 mutation, a cyclin D mutation, a PTEN mutation, an ABL kinase mutation, or a chromosomal abnormality. 16. The method of claim 8, wherein the cancer is a multi-drug resistant (MDR) cancer. 17. The method of claim 8, wherein the cancer is relapsed and/or refractory cancer. 18. The method according to claim 8 further comprising administering at least one other therapy or therapeutic agent. 19. The method according to claim 8 further comprising administering radiation. 20. The method of claim 1, wherein the cancer is lung cancer. 21. The method of claim 1, wherein the cancer is ovarian cancer. 22. The method of claim 1, wherein the cancer is thyroid cancer. 23. The method of claim 1, wherein the cancer is melanoma.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (28)
Peterson Steven F. (West Linn OR), Ampule filling device.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.